Allianz Asset Management
BLCM

Allianz Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Allianz Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,882
Closed -$158K – 2774
2017
Q4 		$158K Sell
1,882
-74
-4% -$7.26K ﹤0.01% 2611
2017
Q3 		$226K Sell
1,956
-102
-5% -$10.7K ﹤0.01% 2566
2017
Q2 		$240K Sell
2,058
-50
-2% -$6.21K ﹤0.01% 2551
2017
Q1 		$260K Sell
2,108
-76
-3% -$9.96K ﹤0.01% 2509
2016
Q4 		$297K Buy
+2,184
New +$388K ﹤0.01% 2470

Other funds holding BLCM

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Ascend Capital Orinda, California $1.99B AUM 10.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allianz Asset Management's BLCM Position: Q1 2018 in Review

Allianz Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2018, closing a stake of 1,882 shares — an estimated $158K sold.

Allianz Asset Management first reported a position in BLCM in Q4 2016 and held it in 5 quarters. The position peaked at $297K in Q4 2016. 90 funds tracked by Wall St. Rank hold BLCM as of Q1 2018.

  • Allianz Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Allianz Asset Management sold 1,882 Bellicum Pharmaceuticals, Inc. shares in Q1 2018, an estimated $158K.
  • Allianz Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2016 and held it in 5 quarters.
  • Allianz Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $297K in Q4 2016.
  • 90 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2018.

Based on Allianz Asset Management's 13F filing for Q1 2018, filed 14 May 2018.